NKTR — Nektar Therapeutics

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 … Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$81.89
Market Cap$2.81B
Float26.9M
Shares Outstanding33.7M
P/E (Forward)34.01
Price/Sales (TTM)50.93
vs. Analyst Target+76.2% to analyst PT
Profit Margin-297.07%
Operating Margin (TTM)-87.54%
Revenue (TTM)$55.2M
Dividend RateNone
Analyst Target Price$144.25 (8 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $153M -$444M $133M -$394M
2021 $102M -$524M $77.0M -$462M
2022 $92.1M -$368M $70.4M -$324M
2023 $90.1M -$276M $53.5M -$243M
2024 $98.4M -$119M $67.7M -$86.7M
2025 $55.2M -$164M $55.2M -$130M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Mar 2025 $10.5M -$50.9M
Jun 2025 $11.2M -$41.6M
Sep 2025 $11.8M -$35.5M
Dec 2025 $21.8M -$36.1M

Ownership & Float

Insider Ownership0.4%
Institutional Ownership57.5%
Short Float13.5%
% of All Funds Holding1.98%
Number of Funds Holding153

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$78.42Near-term / short-term trend
Weekly40-Week SMA$56.82Medium-term trend
Weekly80-Week SMA$35.73Cyclical trend (business cycle)
Weekly200-Week SMA$28.46Secular trend (multi-year)
Monthly10-Month SMA$60.44Near-term monthly trend
Monthly20-Month SMA$37.94Medium-term monthly trend
Monthly40-Month SMA$25.47Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$37.30 support 1.29x 2 months ago
$29.10 support 1.80x 7 months ago
$11.10 support 7.85x 10 months ago

Historical Earnings Reactions (122 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -0.02% 0.00% 49.18% 17.03% -39.20%
1 Day 0.04% -0.67% 43.44% 21.67% -29.25%
1 Week 0.92% 0.57% 51.64% 60.47% -38.79%
2 Weeks -0.07% -0.89% 47.54% 85.36% -56.25%
1 Month 3.84% 1.51% 51.64% 105.70% -49.28%

Next earnings: May 14, 2026 (3 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan3.8%53.1%32
Feb3.0%53.1%32
Mar-0.1%40.6%32
Apr1.7%46.9%32
May0.3%35.5%31
Jun2.6%40.6%32
Jul-2.0%43.8%32
Aug4.5%46.9%32
Sep4.3%46.9%32
Oct-2.3%37.5%32
Nov8.8%68.8%32
Dec1.5%59.4%32

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.12% 43.4% 1513
Tuesday 0.10% 44.3% 1653
Wednesday 0.22% 47.2% 1653
Thursday 0.06% 46.2% 1620
Friday 0.28% 48.7% 1615

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 57.5%

Insider Transactions — Smart Summary

Total insider ownership: 0.4%

12-Month Insider Activity Summary

Total Filings17
Net Value-$1.4M
Net Shares Change-65,879
% of Float-0.2%
C-Suite Filings17
Clusters Detected3

Key Insiders

NameTitleNet ValueFilingsActivity
ROBIN HOWARD W President and CEO -$949,034.358 5 N/A
Zalevsky Jonathan Chief RandD Officer -$265,607.457 4 N/A
Wilson Mark Andrew Chief Legal Officer -$34,196.4 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-05-21 – 2025-05-21 3 3 -$29,423.72 3 C-suite
2025-08-21 – 2025-09-04 5 3 -$138,917.16 5 C-suite
2025-11-25 – 2025-11-25 3 3 -$216,794.32 3 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-22 Zalevsky Jonathan Chief RandD Officer -$137,935.89 Transaction at $35.67, now +129.6%
2025-09-11 ROBIN HOWARD W President and CEO -$311,214.209 Transaction at $46.69, now +75.4%
2025-09-08 ROBIN HOWARD W President and CEO -$430,958.119 Transaction at $36.42, now +124.8%
2025-11-25 Zalevsky Jonathan Chief RandD Officer -$62,801.96 Transaction at $54.28, now +50.9%
2025-11-25 Wilson Mark Andrew Chief Legal Officer -$34,196.4 Transaction at $54.28, now +50.9%
2025-11-25 ROBIN HOWARD W President and CEO -$119,795.96 Transaction at $54.28, now +50.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Nektar Therapeutics (NKTR) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for NKTR on Trend Edge →